ALGN vs. ZBH, WST, COO, SNN, MSA, XRAY, MMSI, HAE, WMGI, and QDEL
Should you be buying Align Technology stock or one of its competitors? The main competitors of Align Technology include Zimmer Biomet (ZBH), West Pharmaceutical Services (WST), Cooper Companies (COO), Smith & Nephew (SNN), MSA Safety (MSA), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), Wright Medical Group (WMGI), and QuidelOrtho (QDEL).
Zimmer Biomet (NYSE:ZBH) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment.
Zimmer Biomet has a net margin of 12.93% compared to Zimmer Biomet's net margin of 11.80%. Zimmer Biomet's return on equity of 14.15% beat Align Technology's return on equity.
Zimmer Biomet received 126 more outperform votes than Align Technology when rated by MarketBeat users. However, 69.64% of users gave Align Technology an outperform vote while only 68.09% of users gave Zimmer Biomet an outperform vote.
Zimmer Biomet has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.
88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 88.4% of Align Technology shares are owned by institutional investors. 1.0% of Zimmer Biomet shares are owned by company insiders. Comparatively, 0.6% of Align Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Zimmer Biomet presently has a consensus target price of $133.75, suggesting a potential upside of 16.15%. Align Technology has a consensus target price of $353.00, suggesting a potential upside of 37.24%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts plainly believe Align Technology is more favorable than Zimmer Biomet.
Zimmer Biomet has higher revenue and earnings than Align Technology. Zimmer Biomet is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zimmer Biomet had 11 more articles in the media than Align Technology. MarketBeat recorded 20 mentions for Zimmer Biomet and 9 mentions for Align Technology. Zimmer Biomet's average media sentiment score of 1.24 beat Align Technology's score of 0.47 indicating that Align Technology is being referred to more favorably in the news media.
Summary
Align Technology beats Zimmer Biomet on 10 of the 17 factors compared between the two stocks.
Get Align Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Align Technology Competitors List
Related Companies and Tools
